Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21164243 | 0.84 | CA12 (0.43) | ANPEPALDH1A1TSHRPAOX | |
| SCHEMBL21164238 | 0.83 | CA12 (0.42) | TSHRPAOX | |
| SCHEMBL21164235 | 0.83 | CA12 (0.42) | TSHRPAOX | |
| SCHEMBL16208729 | 0.82 | OPRM1 (0.54) | OPRM1ANPEPERAP2ALDH1A1TSHR | |
| SCHEMBL29263119 | 0.82 | — | — | |
| SCHEMBL22897317 | 0.81 | ALDH1A1 (0.50) | ANPEPERAP2ALDH1A1TSHRPAOX | |
| SCHEMBL26250240 | 0.81 | ALDH1A1 (0.42) | ANPEPERAP2ALDH1A1TSHRPAOX | |
| SCHEMBL10896616 | 0.80 | ANPEP (0.38) | ANPEPALDH1A1TSHRPAOX | |
| Lithium Ion SCHEMBL1459566 | 0.79 | OPRM1 (0.50) | OPRM1ANPEPERAP2ALDH1A1TSHR | |
| SCHEMBL10643764 | 0.78 | OPRM1 (0.54) | OPRM1ANPEPERAP2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | OPRM1 4043/4885ANPEP 1832/4885ERAP2 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.